#1 Clinical Trials Search in Europe

Istaroxime

Istaroxime is an innovative drug being studied in clinical trials for the treatment of various forms of heart failure, including acute decompensated heart failure and cardiogenic shock. This article explores the ongoing research into istaroxime’s potential to improve cardiac function and outcomes in patients with compromised heart function.

Table of Contents

What is Istaroxime?

Istaroxime is a new medication being developed to treat heart failure. It is currently being studied in clinical trials to evaluate its safety and effectiveness. Istaroxime is given as an intravenous (IV) infusion, meaning it is delivered directly into the bloodstream through a vein.[1]

How Does Istaroxime Work?

Istaroxime works in a unique way compared to existing heart failure treatments. It activates an important protein in heart muscle cells called SERCA2a. This protein helps control how calcium moves in and out of heart cells, which is crucial for proper heart contraction and relaxation.[2]

By activating SERCA2a, istaroxime aims to improve both the contraction (systolic function) and relaxation (diastolic function) of the heart. This dual action makes it different from many current heart failure medications that primarily affect only one of these functions.[3]

What Conditions Does Istaroxime Treat?

Istaroxime is being studied to treat several types of heart failure:

  • Acute decompensated heart failure (ADHF): A sudden worsening of heart failure symptoms that often requires hospitalization.[4]
  • Heart failure with reduced ejection fraction (HFrEF): Where the heart muscle doesn’t contract effectively and has a reduced pumping ability.[3]
  • Heart failure with preserved ejection fraction (HFpEF): Where the heart muscle contracts normally but doesn’t relax properly, leading to poor filling of the heart.[2]
  • Cardiogenic shock: A severe condition where the heart suddenly can’t pump enough blood to meet the body’s needs.[5]

Clinical Trials and Research

Several clinical trials have been conducted or are ongoing to study istaroxime:

  • Phase I studies have evaluated its safety and how it’s processed in the body (pharmacokinetics) in healthy volunteers and heart failure patients.[6]
  • Phase II trials have looked at its effects on heart function, blood pressure, and symptoms in patients with acute heart failure.[7]
  • Ongoing studies are investigating its use in cardiogenic shock and comparing different dosing regimens.[8]

Potential Benefits

Early research suggests that istaroxime may offer several potential benefits for heart failure patients:

  • Improved heart contraction and pumping ability[3]
  • Better relaxation of the heart muscle, allowing it to fill more effectively[2]
  • Increased blood pressure in patients with low blood pressure due to heart failure[5]
  • Reduced congestion (fluid buildup) in the lungs and body[7]
  • Improved kidney function[4]

Possible Side Effects

As with any medication, istaroxime may cause side effects. In clinical trials, some reported side effects have included:

  • Changes in heart rhythm[1]
  • Nausea or vomiting[4]
  • Pain or irritation at the injection site[6]

It’s important to note that as istaroxime is still being studied, not all potential side effects may be known. Researchers are closely monitoring patients in clinical trials to better understand its safety profile.

Current Status and Availability

Istaroxime is still considered an investigational drug. This means it has not yet been approved by regulatory agencies like the FDA for general use. It is only available to patients participating in clinical trials.[8]

If ongoing studies continue to show promising results, istaroxime may become an important new treatment option for heart failure patients in the future. However, more research is needed to fully understand its effectiveness and safety before it can be widely used.

Aspect Details
Drug Name Istaroxime
Conditions Studied Acute Decompensated Heart Failure, Cardiogenic Shock, Heart Failure with Preserved Ejection Fraction
Administration Method Intravenous infusion
Dosage Ranges 0.5 to 1.5 μg/kg/min, varying by study
Primary Outcomes Changes in blood pressure, cardiac function parameters, hemodynamics
Safety Monitoring Cardiovascular events, renal function, arrhythmias, blood chemistry
Potential Mechanisms Improvement of cardiac contraction and relaxation, SERCA2a activation
Trial Phases Phase I to Phase II studies

FAQ

  • What is istaroxime? Istaroxime is a novel drug being investigated for the treatment of heart failure. It works by improving the heart's ability to contract and relax, potentially enhancing cardiac function in patients with compromised heart performance.
  • What types of heart conditions is istaroxime being studied for? Istaroxime is being studied for various forms of heart failure, including acute decompensated heart failure, heart failure with preserved ejection fraction (HFpEF), and cardiogenic shock.
  • How is istaroxime administered in clinical trials? In most clinical trials, istaroxime is administered as an intravenous (IV) infusion. The duration of infusion varies between studies, ranging from 6 hours to 24 hours or more, depending on the specific trial design.
  • What are the main outcomes being measured in istaroxime clinical trials? The main outcomes being measured include changes in blood pressure, cardiac function parameters (such as pulmonary capillary wedge pressure), heart rate, and various echocardiographic measurements. Safety and tolerability are also key aspects being evaluated.
  • Are there any known side effects of istaroxime? As istaroxime is still in clinical trials, its full side effect profile is not yet established. However, researchers are closely monitoring for any adverse events, particularly related to cardiovascular and renal function, during the studies.

Ongoing Clinical Trials on Istaroxime

  • Study on Istaroxime for Patients with Cardiogenic Shock Stage C

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Czechia Italy Poland

Glossary

  • Acute Decompensated Heart Failure (ADHF): A sudden worsening of heart failure symptoms, often requiring hospitalization. It is characterized by fluid buildup in the lungs and other parts of the body.
  • Cardiogenic Shock: A serious condition where the heart suddenly can't pump enough blood to meet the body's needs, often due to a severe heart attack or other heart problems.
  • Pulmonary Capillary Wedge Pressure (PCWP): A measurement of the pressure in the heart's left atrium, which helps assess how well the heart is pumping and if there's fluid buildup in the lungs.
  • Ejection Fraction: A measurement of how much blood the left ventricle pumps out with each contraction. A preserved ejection fraction means the heart is pumping out a normal percentage of blood, but may still not be functioning properly.
  • Echocardiogram: An ultrasound test that uses sound waves to create moving pictures of the heart, allowing doctors to see its size, structure, and how well it's working.
  • Inotrope: A type of medication that changes the force of heart muscle contractions. Istaroxime is being studied for its inotropic effects.
  • SERCA2a: A protein in heart muscle cells that helps regulate calcium levels, which is important for proper heart contraction and relaxation. Istaroxime is thought to affect this protein.

References

  1. https://clinicaltrials.gov/study/NCT00869115
  2. https://clinicaltrials.gov/study/NCT02772068
  3. https://clinicaltrials.gov/study/NCT00616161
  4. https://clinicaltrials.gov/study/NCT02617446
  5. https://clinicaltrials.gov/study/NCT04325035
  6. https://clinicaltrials.gov/study/NCT02477449
  7. https://clinicaltrials.gov/study/NCT00838253
  8. https://clinicaltrials.eu/trial/study-on-istaroxime-for-patients-with-cardiogenic-shock-stage-c/